SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders react to CPI data coming in lower than expected, fueling speculation about potential Fed rate cuts. The community is split, with bulls celebrating new highs and bears questioning the validity of the inflation figures and bracing for a potential pullback. Broader market sentiment appears optimistic, driving discussions about continued momentum and potential year-end targets.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following a Q3 earnings beat, driven by AI PC momentum and strategic cost cuts, sparking discussions about the sustainability of these gains. The community is weighing the impact of datacenter revenue decline against the company's potential in the AI space and the influence of government investments. Analysts are split, with some highlighting the turnaround while others remain cautious about valuation and future growth.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending amid speculation around the latest CPI data release, with many anticipating the numbers and discussing potential market reactions. Community members are debating whether the report will be a "pump or dump" catalyst, while others express skepticism about the data's accuracy and broader market conditions. Talk of a potential Trump-Xi meeting is also circulating, adding to the market's upward momentum.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending on news of soft inflation data increasing speculation around potential rate cuts, which could significantly benefit the fintech company; the community is bullish on the stock's prospects leading up to earnings, discussing a potential breakout above the $30 resistance level. Some are pointing to a similar pattern with other fintechs and anticipating that SoFi will outperform expectations.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors react to its strategic partnership with Palantir to boost enterprise AI adoption, with the community buzzing about its potential impact. Some believe this move will solidify LUMN's role as a key player in AI infrastructure, while others express concerns about the company's debt and timeline for growth. Bullish sentiment is also fueled by discussions around a potential short squeeze and the company's undervalued status in the burgeoning AI sector.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as investors digest recent earnings, lowered 2025 guidance due to a supplier fire, and potential benefits from tariff relief. Community discussions revolve around the impact of these factors on Ford's future performance and whether the stock is undervalued. Bullish sentiment suggests a potential breakout, while others remain cautious due to production challenges.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor is experiencing significant volatility after its revenue guidance fell short of expectations, sparking debate about a potential CEO change. Despite a low P/E ratio and no debt, the stock faces headwinds, with analysts divided on its future and some anticipating further downgrades. Community discussions revolve around bottom-fishing opportunities, potential bounce-backs, and whether the current dip is an overreaction.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to a potential short squeeze amplified by NVIDIA's investment and participation in the GITEX Global conference in Dubai. The community is discussing the stock's high short interest and speculating about news or catalysts. Bullish sentiment also surrounds the company's AI-driven drug discovery platform and potential expansion in the Middle East.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences Inc.

Inhibrx Inc

Inhibrx (INBX) is trending due to positive trial results for their drug Ozekibart in a rare bone cancer trial, chondrosarcoma, which currently lacks approved systemic treatment options. The community is highlighting the potential for a significant improvement in patient outcomes, leading to speculation about a first-mover advantage and potential valuation increase. Some traders caution against FOMO and anticipate a possible offering given the company's cash position.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is trending amid concerns over renewed trade tensions after Trump's tariff threats, leading to market volatility. The community is closely watching how these developments will impact inflation and the Federal Reserve's monetary policy, especially with bank earnings coming up. Some traders believe there may be parallels to the 1929 stock market top.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AXDX Google Accelerate Diagnostics Bankruptcy and you will find a site called &quot;Stretto&quot; that has all of the filings.   Fascinating reading.   Incompetence beyond incompetence.  And the dumbest was likely Indaba who put money into this as a DIP and put out a stalking horse bid. 
 
Bottom line?  MicroGuy was right and I was wrong.   THere was and is no demand for a combined diagnostic blood and isoaltes. 
 
The irony?  BDX liked Pheno!   And Indaba discontinued it!   Had AXDX sold to BDX instead of holding out for Wave it&#39;s likely that Pheno would be part of BDX&#39;s toolbox and AXDX would have avoided bankruptcy. 
 
By the way?  I think this is going to go Chapter 7.

StockTwits Web

Accelerate Diagnostics Inc

 Google Accelerate Diagnostics Bankruptcy and you will find a site called "Stretto" that has all of the filings.   Fascinating reading.   Incompetence beyond incompetence.  And the dumbest was likely Indaba who put money into this as a DIP and put out a stalking horse bid. 
 
Bottom line?  MicroGuy was right and I was wrong.   THere was and is no demand for a combined diagnostic blood and isoaltes. 
 
The irony?  BDX liked Pheno!   And Indaba discontinued it!   Had AXDX sold to BDX instead of holding out for Wave it's likely that Pheno would be part of BDX's toolbox and AXDX would have avoided bankruptcy. 
 
By the way?  I think this is going to go Chapter 7.

Esau McIntosh

@Esau815 I was following along with the bankruptcy filings too. According to the testimony of the Parella Weinberg Partner, they reached out to 18 strategic buyers and conducted MGMT &amp; Due-Diligence meetings with 9 buyers who signed NDAs between Jan - April 2025 before filing CH11 in May. Then during bankruptcy, Parella contacted an additional 21 buyers, 2 who signed  NDAs and got materials and the 9 strategics from  before were contacted again and all declined to put in a bid above the stalking horse DIP creditor
Bid by INDABA. So 11 buyers passed. Indaba gets this whole company for $42M (which was their note/creditor bid). Wild. 

Can’t believe how wrong I was. Worst investment over. Can’t believe this company and the board and C-Suite blew thru $720M on this endeavor since inception. 

Where do you see that Indaba discontinued Pheno? Where does it say BDX was interested in Pheno? Was there an acquisition offer back from 2023 when they signed commercial partnership with BDX?

StockTwits for iOS

 I was following along with the bankruptcy filings too. According to the testimony of the Parella Weinberg Partner, they reached out to 18 strategic buyers and conducted MGMT & Due-Diligence meetings with 9 buyers who signed NDAs between Jan - April 2025 before filing CH11 in May. Then during bankruptcy, Parella contacted an additional 21 buyers, 2 who signed  NDAs and got materials and the 9 strategics from  before were contacted again and all declined to put in a bid above the stalking horse DIP creditor
Bid by INDABA. So 11 buyers passed. Indaba gets this whole company for $42M (which was their note/creditor bid). Wild. 

Can’t believe how wrong I was. Worst investment over. Can’t believe this company and the board and C-Suite blew thru $720M on this endeavor since inception. 

Where do you see that Indaba discontinued Pheno? Where does it say BDX was interested in Pheno? Was there an acquisition offer back from 2023 when they signed commercial partnership with BDX?

Chewey

@cheweyb224 BDX filed a motion to terminate the contract.  In that filing they mentioned that Indaba discontinued Pheno.  They had made a sale of 8 machines in Italy that they could not honor as a result.  That breach caused the filing. 
 
I missed the Perella filing.  Thanks for the update. 
 
My worst investment ever.  At the end of the day?  MicroGuy was right.  There was simply no need for rapid AST.  The BIg Error was believing that BM&#39;s Specific purchase for $430MM set the market and need for AST when in fact it likely showed that doctors didn&#39;t use it and that purchase was a mistake. 
 
AXDX&#39;s biggest error is that they should have sold to BDX when they had the chance.

 BDX filed a motion to terminate the contract.  In that filing they mentioned that Indaba discontinued Pheno.  They had made a sale of 8 machines in Italy that they could not honor as a result.  That breach caused the filing. 
 
I missed the Perella filing.  Thanks for the update. 
 
My worst investment ever.  At the end of the day?  MicroGuy was right.  There was simply no need for rapid AST.  The BIg Error was believing that BM's Specific purchase for $430MM set the market and need for AST when in fact it likely showed that doctors didn't use it and that purchase was a mistake. 
 
AXDX's biggest error is that they should have sold to BDX when they had the chance.

@Esau815 I was also right.  I&#39;m the end user that you mocked for telling you that the product didn&#39;t fit well in a clinical setting.

 I was also right.  I'm the end user that you mocked for telling you that the product didn't fit well in a clinical setting.

Troy Longtin

@troy5190 I have readily admitted that I was disastrously wrong regarding Wave.   I&#39;ve done a mental autopsy.   In the end?  My biggest mistake?   Not recognizing that Biomereiux&#39;s purchase of Specific was indeed a mistake.  I did not have information that Biomerieux&#39;s client base were not making actionable decisions.   Indeed, BDX likely partnered with AXDX to counter that move--and, when seeing that clinicians weren&#39;t using Specific had no interest in acquring AXDX. 
 
As a general rule?  Big money has more credibility than anonymous internet posters.   In this case the general rule was wrong.  Big Money invested in Specific.   Big money invested in AXDX and Selux.   Bottom line?    There&#39;s no need for Rapid AST.

 I have readily admitted that I was disastrously wrong regarding Wave.   I've done a mental autopsy.   In the end?  My biggest mistake?   Not recognizing that Biomereiux's purchase of Specific was indeed a mistake.  I did not have information that Biomerieux's client base were not making actionable decisions.   Indeed, BDX likely partnered with AXDX to counter that move--and, when seeing that clinicians weren't using Specific had no interest in acquring AXDX. 
 
As a general rule?  Big money has more credibility than anonymous internet posters.   In this case the general rule was wrong.  Big Money invested in Specific.   Big money invested in AXDX and Selux.   Bottom line?    There's no need for Rapid AST.

@Esau815 @troy5190  
100% in agreement with you final verdict. 
 
Now, what’s interesting is that there are a couple of dozen companies still trying to bring their ”rapid AST” solutions to the market now. 
 
It’s mind boggling, given the public disclosure as a result of Axdx chapter 11.  
Good read,  nonetheless.

  
100% in agreement with you final verdict. 
 
Now, what’s interesting is that there are a couple of dozen companies still trying to bring their ”rapid AST” solutions to the market now. 
 
It’s mind boggling, given the public disclosure as a result of Axdx chapter 11.  
Good read,  nonetheless.

MicroGuy

My error was  believing that Biomereiux&#39;s purchase of Specific was both necessary and being used and wanted by physicians.    In the end?   Not enough physicians were using Rapid AST to make actionable decisions.   What I thought would be an arms race to compete was basically a wasted purchase and BM&#39;s competitors recognized ust that.   Second biggest loss ever for me. 
 
Lesson learned is to follow sales.   Let&#39;s assume that BDX had a competent sales force.   That they were unable to sell Pheno was telling.   I should have picked up the signs.

My error was  believing that Biomereiux's purchase of Specific was both necessary and being used and wanted by physicians.    In the end?   Not enough physicians were using Rapid AST to make actionable decisions.   What I thought would be an arms race to compete was basically a wasted purchase and BM's competitors recognized ust that.   Second biggest loss ever for me. 
 
Lesson learned is to follow sales.   Let's assume that BDX had a competent sales force.   That they were unable to sell Pheno was telling.   I should have picked up the signs.

@Esau815  
Indeed, purchase of Specific threw off many, including BMX itself - can’t place any units now. 
Big money was wrong here as well.

  
Indeed, purchase of Specific threw off many, including BMX itself - can’t place any units now. 
Big money was wrong here as well.